Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited

Piramal '\V Pharma Limited 10th August, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Administrative Committee of the Board of Directors of the Company, acting under the authority delegated by the Board, has approved the exercise of the Company's call option for acquisition of an additional 41% equity stake in Yapan Bio Private Limited ("Yapan") an associate company of the Company, from its existing shareholders (‘the Proposed Transaction’). Consequent to the exercise of the call option, the Company is engaged in discussions with the promoters/ shareholders of Yapan regarding various matters required for consummation of the Proposed Transaction. The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalized. The Company will make appropriate disclosures along with the details as required under Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Securities Exchange of Board of India Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30, 2026, upon execution of definitive documentation and completion of the Proposed Transaction. Yapan is a Contract Development and Manufacturing Organization that specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics. The Proposed Transaction will result in an increase in the Company’s shareholding in Yapan from the existing 33.33% to approximately 74%, and consequently, Yapan will become a subsidiary of the Company. Kindly take the above on record. Thank you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com